Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up. - Wikidata - awgldk - TriplyDB

Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up.

Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up.

http://www.wikidata.org/entity/Q31440594

about

Lamivudine or adefovir dipivoxil alone or combined with immunoglobulin for preventing hepatitis B recurrence after liver transplantation Lamivudine or adefovir dipivoxil for preventing hepatitis B recurrence after liver transplantation Management of HBV Infection in Liver Transplantation Patients KASL clinical practice guidelines: management of chronic hepatitis B Change of strategies and future perspectives against hepatitis B virus recurrence after liver transplantation Treatment of chronic hepatitis.Clinicopathological features of hepatitis B virus recurrence after liver transplantation: eleven-year experience.Prevention of fungal and hepatitis virus infections in liver transplantation.Hepatitis B and C in the liver transplant recipient: current understanding and treatment.A concise update on the status of liver transplantation for hepatitis B virus: the challenges in 2002.Treatment of hepatitis B and C after liver transplantation. Part 1, hepatitis B.KASL Clinical Practice Guidelines: Management of chronic hepatitis B.Prevention and treatment of recurrent Hepatitis B after liver transplantation: the current role of nucleoside and nucleotide analogues Review article: hepatitis B and liver transplantation.Prevention of hepatitis B virus recurrence after liver transplantation.Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation.Hepatitis B immunoglobulins and/or lamivudine for preventing hepatitis B recurrence after liver transplantation: a systematic review.Review of the pharmacological management of hepatitis B viral infection before and after liver transplantation.HBIG Remains Significant in the Era of New Potent Nucleoside Analogues for Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation.Rational Basis for Optimizing Short and Long-term Hepatitis B Virus Prophylaxis Post Liver Transplantation: Role of Hepatitis B Immune Globulin.Current clinical evidence for nucleos(t)ide analogues in patients with HBV-related hepatocellular carcinoma.Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: Results up to 8 years.Comparative efficacy of oral nucleotide analogues for the prophylaxis of hepatitis B virus recurrence after liver transplantation: a network meta-analysis.Efficacy and tolerability of Entecavir for hepatitis B virus infection after hematopoietic stem cell transplantation.Management of HBV infection during immunosuppressive treatment Clinical-pathological analysis of hepatitis B virus recurrence after liver transplantation in Chinese patients.Different effect of HBV vaccine after liver transplantation between chronic HBV carriers and non-HBV patients who received HBcAb-positive grafts.Lamivudine for hepatitis B after liver transplantation.Beneficial effect of lamivudine for hepatitis B transplant recipients.Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation.Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis.The long-term efficacy of nucleos(t)ide analog plus a year of low-dose HBIG to prevent HBV recurrence post-liver transplantation.No hepatitis recurrence using combination prophylaxis in HBV-positive liver transplant recipients with YMDD mutants.HBV vaccination in liver transplant recipients: not an effective strategy in the prophylaxis of HBV recurrence.Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B.Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance.Significance of hepatitis B virus genotype in liver transplantation for chronic hepatitis B.

P2860

Q24234338-65B6832E-2284-4F9C-A44B-731786CE6606 Q24244437-E98DFD81-9096-46B0-8F19-B1336D282EE9 Q24529103-207E3982-ECA3-4DCA-9CBE-DA403C4E3DD8 Q26752475-7CBC06D8-E81A-4836-9CDC-C4730E2866E4 Q26784241-B9EA101D-C530-4719-9110-F76366FCFBC3 Q28364240-3C5C52CA-8E67-44C6-BE56-8DB076C8841D Q34029115-4EAE77AC-74FB-425B-BA68-BAF95B8331AB Q34271696-1BFE0178-FE4E-4715-A25E-F6C22650BAB3 Q34426421-C925959D-644D-453B-9536-3AE9B301A6BD Q34499694-C946CE7A-9E02-448F-8F56-2F47DAC67E5A Q36028324-8253DC4E-C2EC-4857-8647-8E0F32A4F1CC Q36153966-02DBD1B3-AEDE-4681-BCC9-AA6513C9B7A7 Q36442537-23FAF981-A506-4C66-9C40-B9537D98E93E Q36447557-2A836D8B-ADD0-4D08-8A85-830519D158F3 Q36652077-F21EE534-BA0F-4830-90F6-B71B1DC77C74 Q37495757-C5D2BD0C-BB20-413F-B956-38816A04A99B Q37764964-44619F76-8A49-4FAC-B5B3-F778B9E0FDF7 Q38177252-C42A4172-ABC8-403B-B4CA-B83EF0CA6B5A Q38218762-4A4BA1BB-AAD7-4B74-96ED-41A61291ECAC Q38514411-3164B238-3516-4FCE-AAAF-31FD0EEBCC3E Q38665203-93910C6E-A7EA-41FB-B579-917C130B2E66 Q40261285-F071AEE5-81F5-4E76-BCF2-A5E74B466635 Q40588229-38A51648-6F01-42F5-81C0-9E560B0D278E Q41756602-AA7008C5-D9B6-4FB6-B4DF-39DBFD9E940B Q41859437-96F28426-867F-41AC-A0D8-5BA480274150 Q42244681-1E26F4D5-4101-4568-8F43-B6746A1C62BD Q43640407-E4E1DB1C-A9C6-4747-80C1-664038B34D0F Q43666869-71F36B98-11D0-42B7-BF1E-2C8C77C252E2 Q43988925-AB9462C3-05EA-41D6-8517-81B4CCE85437 Q44124730-604159DE-77D7-47D7-9275-1040C60BD584 Q44254904-123A68C1-55F1-479F-BA0B-FA193047E8CD Q44425133-785E9D54-C207-4E9D-A0E3-5AA9AD02CBCA Q45250862-48B38369-8D80-44AC-A15C-4202B3287F54 Q45273548-2702BF16-6BD5-4A9C-9687-E205902F1CDA Q45299212-12DDB65D-874D-4612-93C7-F96EA618AFED Q45365708-7A39FDC6-CA60-469D-9CF8-AFC3E380C677 Q45438761-AE222CC8-2813-4E4E-8A69-577344764D54

P2860

Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up.

http://www.wikidata.org/entity/Q31440594

description

2000 nî lūn-bûn

@nan

2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Lamivudine without HBIg for pr ...... atitis B: long-term follow-up.

@ast

Lamivudine without HBIg for pr ...... atitis B: long-term follow-up.

@en

type

label

Lamivudine without HBIg for pr ...... atitis B: long-term follow-up.

@ast

Lamivudine without HBIg for pr ...... atitis B: long-term follow-up.

@en

prefLabel

Lamivudine without HBIg for pr ...... atitis B: long-term follow-up.

@ast

Lamivudine without HBIg for pr ...... atitis B: long-term follow-up.

@en

P1433

Q31440594-81D0A274-C4E1-4BC4-B164-A593C1F227CD

P1476

Q31440594-AC1B6075-E5C8-4655-B23E-6D1D24950288

P2093

Q31440594-1256D2EC-8367-4700-83EF-82A2A33BCC6D

Q31440594-392A0D8E-94AA-4041-97C8-171766488595

Q31440594-3A843C85-3BD2-433B-A9E6-7F15C78AB4C1

Q31440594-3E592598-8B64-4E27-8D29-2E1BCD745D36

Q31440594-46B73CD4-5D5C-4E4D-B904-CD14684542AF

Q31440594-6CA33A0B-6BA5-445D-BE42-E210149C9F6D

Q31440594-BA3E44D0-2637-458C-9A3A-13434EC9472A

Q31440594-D30EF5B7-11CF-40EC-A4D8-C990EC0784D8

Q31440594-E8414429-32B0-4E97-B128-D09194B4405E

Q31440594-F19AA93A-0E40-4303-8036-59E7B64CB87F

P304

Q31440594-43ED9AA5-8BDA-4912-8366-3CE03E0C9CBD

P31

Q31440594-C69F8148-EE6A-408B-A8B0-DC0A99239EF4

P356

Q31440594-3BD4D333-0D3F-4FFA-BE29-9B14DDBA6107

P433

Q31440594-1DCC012E-DD6B-4DBE-A93B-1FA0B89FDB67

P478

Q31440594-8B0DB2A1-BFE1-4BBF-80B5-5FAE6857E551

P577

Q31440594-3BB5F8E9-FE21-41B0-8F8E-E286061A62F8

P698

Q31440594-6C8A6EC6-9236-4A3B-A07D-9686957F9B0E

P356

00007890-200009150-00018

P1433

Transplantation

P1476

Lamivudine without HBIg for pr ...... atitis B: long-term follow-up.

@en

P2093

Ahmed M

http://www.w3.org/2001/XMLSchema#string

Anschuetz G

http://www.w3.org/2001/XMLSchema#string

Barrett C

http://www.w3.org/2001/XMLSchema#string

Burroughs A

http://www.w3.org/2001/XMLSchema#string

Dhillon AP

http://www.w3.org/2001/XMLSchema#string

Dusheiko G

http://www.w3.org/2001/XMLSchema#string

Elias E

http://www.w3.org/2001/XMLSchema#string

Grellier L

http://www.w3.org/2001/XMLSchema#string

Hubscher S

http://www.w3.org/2001/XMLSchema#string

Mutimer D

http://www.w3.org/2001/XMLSchema#string

P304

809-815

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/00007890-200009150-00018

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P577

2000-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11003363

http://www.w3.org/2001/XMLSchema#string